证券代码：603858 证券简称：步长制药 公告编号：2025-187 山东步长制药股份有限公司 关于全资子公司药品生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）近日获悉全资子公司保定 天浩制药有限公司（以下简称"保定天浩"）获得河北省药品监督管理局许可， 同意保定天浩《药品生产许可证》车间生产线、药品委托情况的变更，其他内容 不变，现将相关情况公告如下： 一、药品生产许可证相关情况 企业名称：保定天浩制药有限公司 注册地址：河北省定兴县兴华东路 128 号 法定代表人：王益民 许可证编号：冀 20150057 分类码：AhzBh 企业负责人：殷文忠 质量负责人：卢颖 生产地址和生产范围：河北省定兴县兴华东路 128 号：搽剂，软膏剂，片剂， 溶液剂（外用），乳膏剂，凝胶剂，灌肠剂，油剂，硬胶囊剂，颗粒剂，喷雾剂 （仅限注册申报使用）*** 山东省菏泽市中华西路 1668 号（山东步长神州制药有限公司）：集团内共 用中药提取、颗粒剂*** 1 有效期至：203 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 9 月 16 日召开 第五届董事会第三十二次会议，审议通过了《关于上海合璞医疗科技有限公司拟 对外投资的议案》，根据公司总体发展规划，为促进公司控股子公司上海合璞医 疗科技有限公司（以下简称"上海合璞"）的经营发展，上海合璞拟对外投资共 490 万元，分别与济南恒德科技发展有限公司（以下简称"济南恒德科技"）、上 海裹鼎科技有限公司（以下简称"上海裹鼎科技"）共同投资设立两家新公司山 东合璞锐诚医疗科技有限公司（以工商注册登记为准）、湖北合璞医疗科技有限 公司（以工商注册登记为准）。山东合璞锐诚医疗科技有限公司注册资本 400 万 元，其中上海合璞出资 280 万元，持股比例 70%；济南恒德科技出资 120 万元， 持股比例 30%。湖北合璞医疗科技有限公司注册资本 300 万元，其中上海合璞出 资 210 万元，持股比例 70%；上海裹鼎科技出资 90 万元，持股比例 30%。 2025 年 9 ...

2025年9月16日，山东步长制药股份有限公司第五届董事会第三十二次会议通过议案，其控股子公司上 海合璞医疗科技有限公司拟共投资490万元，分别与济南恒德科技、上海裹鼎科技设立山东合璞锐诚医 疗科技有限公司、湖北合璞医疗科技有限公司，上海合璞均持股70%。近日，两家新公司完成工商登记 注册手续。山东合璞锐诚医疗科技注册资本400万元，9月24日成立；湖北合璞医疗科技注册资本300万 元，9月26日成立。相关信息已在上海证券交易所网站披露。 ...

Core Viewpoint - The article highlights the modernization of traditional Chinese medicine (TCM) through digitalization and innovative technologies, particularly focusing on the practices of Shandong Buchang Pharmaceutical Co., Ltd. Group 1: Digitalization and Traceability - Buchang Pharmaceutical has established a digital traceability system covering 350 nodes for Chinese medicinal materials, allowing for full lifecycle tracking from seedling to product delivery [4][6] - The system has accumulated traceable information for over 200,000 acres of standardized medicinal material management, addressing the industry's "difficult traceability" issue [6] Group 2: Quality Control and Raw Material Sourcing - The company emphasizes the importance of selecting the right cultivation areas to ensure the quality of medicinal materials, with specific bases in the Yimeng Mountains and Xinjiang [3] - The effective components in the medicinal materials from these regions exceed pharmacopoeia standards by over 40% due to favorable growing conditions [3] Group 3: Technological Innovations in Production - Buchang Pharmaceutical has implemented several technological breakthroughs in the production process, including precise material delivery, stable granulation, and intelligent drying technologies, resulting in a 40% reduction in energy consumption and a doubling of production efficiency [7] - The company has transitioned from traditional experience-based methods to a scientific verification approach in drug development, establishing a comprehensive quality control research system [9] Group 4: Integration of Traditional and Modern Practices - The modernization of TCM at Buchang Pharmaceutical does not discard traditional methods but enhances them with technology, converting experiential knowledge into digital parameters for precise control [10] - The DCS system allows for temperature control within ±0.1℃, replicating traditional extraction methods while improving yield and consistency by over 10% compared to manual operations [10]

/ 机构调研pro小程序 步长制药分析师会议 调研日期：2025年09月26日 调研行业：中药 参与调研的机构：投资者等 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 | | ...

Core Viewpoint - The announcement of a mid-year cash dividend by the company reflects its strong operational performance and commitment to shareholder returns, marking the first mid-year dividend since its listing [1][2]. Dividend Distribution - The company will distribute a cash dividend of 0.39 yuan per share, totaling over 411 million yuan, based on a total share capital of 1,054,568,442 shares, to be paid on September 26 [1]. - Cumulatively, the company has distributed over 7.9 billion yuan in dividends and repurchased shares worth over 1.7 billion yuan since its listing in 2016 [2]. - The company maintained a consistent dividend policy even during challenging times, with notable dividends in 2019 and 2022, showcasing its commitment to shareholder returns [2]. Industry Comparison - Compared to peers, the company's mid-year dividend of 0.39 yuan per share is positioned at a relatively high level within the industry, with a dividend yield of 2.52%, surpassing several competitors [3]. - Other pharmaceutical companies have also announced mid-year dividends, indicating a trend towards increased cash dividends in the sector [3]. Financial Performance - The company's solid dividend policy is supported by strong operational performance, with healthy cash flow from operating activities providing a robust financial foundation for the dividend [4]. - The company is expanding its portfolio in high-tech areas such as chemical drugs, biological drugs, and vaccines, with a total of 457 valid patents and 209 products under development [4]. Corporate Governance and Social Responsibility - The company's consistent cash dividend policy reflects its governance quality and commitment to attracting long-term investors [5]. - The company has engaged in social responsibility initiatives, sponsoring public welfare activities for 18 years and contributing over 32 billion yuan in taxes, demonstrating its commitment to societal value [6][7].

Company Overview - Shandong Buchang Pharmaceutical Co., Ltd. is located in Mudan District, Heze City, Shandong Province, established on May 10, 2001, and listed on November 18, 2016 [1] - The company's main business involves the research, production, and sales of traditional Chinese medicine, with revenue composition as follows: Traditional Chinese medicine 82.34%, chemical drugs 10.08%, medical devices 6.61%, and others 0.97% [1] Financial Performance - For the period from January to June 2025, Buchang Pharmaceutical achieved operating revenue of 5.664 billion yuan, a year-on-year increase of 4.27%, and a net profit attributable to shareholders of 628 million yuan, a year-on-year increase of 171.24% [2] - Since its A-share listing, the company has cumulatively distributed dividends amounting to 7.948 billion yuan, with 1.609 billion yuan distributed over the past three years [2] Stock Market Activity - As of September 23, the stock price of Buchang Pharmaceutical was 18.09 yuan per share, with a market capitalization of 19.077 billion yuan [1] - The stock has seen a year-to-date increase of 14.49%, but has declined by 4.08% over the last five trading days and 6.66% over the last twenty days [1] - The company experienced a net outflow of main funds amounting to 6.267 million yuan on September 23, with significant selling pressure observed [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Buchang Pharmaceutical was 55,200, a decrease of 7.32% from the previous period, while the average circulating shares per person increased by 7.89% to 20,054 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the seventh largest, holding 11.8743 million shares, an increase of 4.0148 million shares from the previous period [2]

（文章来源：证券日报） 证券日报网讯 9月22日晚间，步长制药发布公告称，公司近日获悉全资子公司山东康爱制药有限公司 （以下简称"山东康爱"）获得山东省药品监督管理局许可，同意山东康爱《药品生产许可证》受托情况 的变更。 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-185 山东步长制药股份有限公司 关于全资子公司药品生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）近日获悉全资子公司山东 康爱制药有限公司（以下简称"山东康爱"）获得山东省药品监督管理局许可， 同意山东康爱《药品生产许可证》受托情况的变更，其他内容不变，现将相关情 况公告如下： 质量负责人：杨爱芝 生产地址和生产范围：山东省菏泽市高新区中华西路 1566 号；冻干粉针剂、 小容量注射剂、口服溶液剂*** 有效期至：2030 年 7 月 27 日 二、药品生产许可证副本变更情况 一、药品生产许可证相关情况 企业名称：山东康爱制药有限公司 注册地址：山东省菏泽市高新区中华西路 1566 号 法定代表人：高祥祥 许可证编号：鲁 20160272 分类码：AhCh 企业负责人：高祥祥 同意在生产地址:山东省菏泽市高新区中华西路 1566 号，增加受托生产。(1) 1 委托方:山东丹红制药有限公司，生产品种 ...

法定代表人：李龙广 证券代码：603858 证券简称：步长制药 公告编号：2025-186 山东步长制药股份有限公司 关于控股子公司完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日召开 第五届董事会第二十九次会议，审议通过了《关于控股子公司住所变更的议案》， 公司控股子公司山东步长金钥匙医药科技有限公司（以下简称"步长金钥匙"） 因经营管理之需要，拟对其住所进行变更。具体内容详见公司 2025 年 8 月 16 日披露于上海证券交易所网站（www.sse.com.cn）的《关于控股子公司住所变更 的公告》（公告编号：2025-149）。 近日，步长金钥匙已完成工商变更登记手续，并取得莱芜高新技术产业开发 区市场监督管理局换发的营业执照，变更后的相关信息如下： 名称：山东步长金钥匙医药科技有限公司 类型：其他有限责任公司 2025 年 9 月 23 日 2 注册资本：伍佰万元整 成立日期：2025 年 01 月 08 日 住所： ...